GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple ...

Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis ...

Nine markets, six questions, one page to pin above the desk. From Japan's 50,000-patient line to China's brand-new seven-year exclusivity, this is what a rare disease developer actually gets across ...

Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. announced a research agreement to evaluate the use of Lunit SCOPE IO, ...

Through its collaboration with OASES and partners across the healthcare ecosystem, Johnson & Johnson looks forward to: ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, shared the first data from a ...

Coreline Soft has received U.S. Food and Drug Administration (FDA) 510 (k) clearance for AVIEW Aorta Metrics, its AI-powered ...

Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, ...

Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...

New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building ...

CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry ...

The IMPACT31 trial will enrol 90 high-risk liver cancer patients across the US and Asia-Pacific to evaluate GNOS-PV02 ...